New! View global litigation for patent families

US2888455A - New sulfonamide and process for producing the same - Google Patents

New sulfonamide and process for producing the same Download PDF

Info

Publication number
US2888455A
US2888455A US68146857A US2888455A US 2888455 A US2888455 A US 2888455A US 68146857 A US68146857 A US 68146857A US 2888455 A US2888455 A US 2888455A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
methylisoxazole
compound
benzene
group
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
Kano Hideo
Nishimura Haruo
Nakajima Kiyoshi
Ogata Kazuko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14Nitrogen atoms
    • C07D261/16Benzene-sulphonamido isoxazoles

Description

United States PatentQ ce 2,888,455

a en ed May 26, 195.52

In, contrast to the foregoing results, the in vivo testing 2,888,455 of the same compounds demonstrated a clear superiority for the unique compound of the invention. That is to NEW E say, by administering our sulfonamide derivative to 5 groups consisting of ten mice each weighing 17-18 HideqKano, Kamikyo-ku, Kyotorshi, liaruo Nishimura, grams, via the oral route at 2, 24, 48, 72 and 96 hours, Ashlya'shl Kiyoshl N l N y d g l, respectively, following intraperitoneal injection of Osaka, f Kazllko 8 Nasano-shi, Japan, assign l-OOMLD of the microorganism Diplococcus pneumoniae toshwnogla (type 1), 80 and 10 survival percentages at the dosage No Drawing. Application September 3,1957 10 level of 1 and gr pe gram o y i t Serial No. 681,468 re bserved, whereas sulfisoxazole gave 50 and 0 percent at the dosage level of 2 and; 1 milligrams in analogous Claims priority, application Japan September 4, 1956 experiments. The infections were fatal to all untreated 2 Claim (CL 2 39 9 animals; the ST-100 being two days. As a result of these experiments, it was shown that the sulfonamide Th present i ti l t t th provision of a of the invention is more than two times more effective new. sulfonamide derivative, and to a process for prothan sulfisoxazole when administered via the oral route.

ducing; the same. 3-sulfanilamido-5-methylisoxazole may be represented S-sulfanilamido isoxazoles and methods for producing y the following Structural formula! such compoundshave been described in US. Patent No.

2,43Q,09,4. The synthesis of 3-sulfanilamidoisoxazoles, HC -CNH'.S 0,NH,

however, in which the sulfanilamido group is bonded i,

tothe third position of the isoxazole nucleus has not been reported heretofore in the literature. The principal 0 object of the, present invention is to provide such a Thenovel compound of the invention may be produced compound possessing chemotherapeutic utility equivalent by condensing 3-amino-5'-methylisoxazole with a corn. to that normally possessed by known sulfa derivatives pound carrying a p-amino-or a p-substituted benzene of the general. class described. In particular, the invensulfonyl group, and thereafter changing the Nf -subtion contemplates the provision of the compound 3-sulstituent into a N -amino group in the latter condensation. fanilamido-S-methylisoxazole. This reaction may be illustrated by the following During the course of a systematic search for new structural equations:

sulfonamide compounds structurally related to sulwherein R is the residue of an easily reactive p-subfisoxazole, and' evaluation of the antibacterial activity stituted benzene sulfonic acid derivative; and R repof such compounds, we have succeeded in synthesizing resents a group which is convertible to an amino group. 3.-sul-fanilarnido-5-methylisoxazole, and have found that In the foregoing reaction, the condensation steps A this compound exhibits a high degree of antibacterial and A may be effected without the use of a solvent, activity in both in vitro and invivo tests. That is to but an inert solvent medium generally insures the promosay, the antibacterial activity of the unique compound tionof uniform reactions. In general, the type of solvent of the invention in vitro is similar to that of sulfisoxazole, employed is determined by its non-reactivity, but if whereas the antitubercular activity in vitro of said comsulfonyl halides are used as the easily reactive derivapound is found to be superior to that of sulfisoxazole. tives of benzene sulfonic acid, basic or basiiied solvents The in vitro data for the novel compound of the invensuch as pyridine, picoline or acetone with sodium tion as compared with sulfisoxazole are as follows: bicarbonate are preferably employed. We prefer to employ benzene sulfonyl halides, and particularly the m chloride, as the easily reactive derivative of benzene Test organisms fig sulfonic acid, but other functional derivatives of benzene (11101) sulfonlc ac1d, for example, the acid ester, may also be (11101) employed.

Step B in the foregoing synthesis is eifected subsequent are; ta s 8888888 F the step 2 which emerge-benzene sulfonamido Shigella flEITLGTiZ, 2(Z 1:500, 000 1:500, 000 isoxazole, bearing a substitutent convertible to an ammo iiggg ggg figgg ggg group at the fourth position of the benzene nucleus, is Shigella flezneri l, 4a.- 1=500,000 1:500, 000 produced. The aforementioned substituent at the 4-pos1- 5255335221 3 8 383 iiggg'ggg tion of the reactive benzene sulfonic acid derivatives sI mp Mp: 1:200: 000 1:200: 000 may include any of the nitro-acylamino or carbalkox-yms {E588 88g iiggg ggg amino groups. The type of reaction employed in step B Pseudomonas aeruginosa... 10, 000 10,000 is determined largely by the nature of substituent R. F ,-fff s $881888 ii88888 That is to say, when R is an acylamino radical such as $232 8% 338:838 the acetamino group or a carbalkoxyamino radical such Mycobac. tuberculosis nsmvm 1=10,000 1:2,000 as the carbethoxy amino group, the intermediate should be saponified, whereas when R, is a m'tro group, the intere 3 mediate should be reduced. These reactions may be effected in accordance with standard techniques, for example, by heating with aqueous sodium hydroxide solution for the hydrolysis reaction, or by treating with zinc dust and hydrochloric acid for the reduction reaction.

It should be noted that the starting material 3-arnino- S-methylisoxazole utilized in the foregoing reaction is also a new compound. It may be obtained by hydrolysis of ethyl 5-methylisoxa2ole-3-carbamate succeeding to the Curtius degradation of 5-methylisoxazole-3-carboxylic acid according to Freiris method (cf. CA-26, 5953, 1932). The compound is prismatic and melts at 6l-62 C.

It is believed that our invention may be best understood by reference to the following specific examples showing the application of the foregoing techniques to the production of the unique sulfonamide of the invention:

Example (a) Preparation of 3-amin0-5-methylisoxazole.1.7 g. of ethyl 5-methylisoxazole-3-carbamate was heated on a boiling water-bath with 5 cc. of a 10% aqueous sodium hydroxide solution for 8 hours, then the reaction mixture was extracted several times with ether or benzene and the extract was cooled succeeding to the removal of the solvent and drying. The residue was solidified after a while and gave prismatic crystals, melting point 6l-62 C., of 3-amino-5-methylisoxazole by recrystallization from benzene.

Elemental analysis for empirical formula C H ON Calculated-C, 48.97; H, 6.16; N, 28.57. FoundC, 49.42; H, 6.50; N, 28.28.

This substance is a new compound and is also obtained by a similar hydrolysis of benzyl 5-methylisox azole-3-carbamate, melting point 80-81 C.

(b) Preparation of 3 acetylsitlfanilamido 5 methylisoxazole.0.9 g. of 3-amino-5-methylisoxazole in 5 cc. of pyridine was allowed to react with 2.0 g. of acetylsulfanil chloride accompanied with the generation of heat. After about one hour, water was added to the reaction mixture and the crystal precipitated out was recrystallized from alcohol to give 2.5 g. of 3-acetylsulfanilamido-S-methylisoxazole, melting point (decomposition) 220221 C.

Elemental analysis for empirical formula C H O N S: CalculatedC. 48.81; H, 4.40; N, 14.33. Found-C, 49.08; H, 4.63; N, 14.05.

A similar result was obtained by the condensation in a sodium bicarbonate-acetone medium.

I (6) Preparation of .i-sulfanilamido -5 -methylisoxaz0le.2 g. of 3-acetylsulfanilamido-5-methylisoxazole was heated with 10 cc. of an aqueous sodium hydroxide aesaaee 6L solution on a Water-bath for one hour and after cooling the reactant was acidified by addition of acetic acid. The precipitate thus formed was recrystallized from dilute alcohol to give 15 g. of colorless prisms of 3-sulfanilamido-S-methylisoxazole, melting point 167 C.

Elemental analysis for empirical formula C H O N S: Calcula'tedC, 47.43; H, 4.35; N, 16.60. FoundC, 47.96; H, 4.49; N, 16.52.

This compound is bitterish and by acetylation in pyridine base gave the corresponding N ,N -diacetyl compound, melting point 209210 C.

Having thus described the subject matter of our inventioi, what it is desired to secure by Letters Patent is:

1. The chemical compound 3-sulfanilamido5-methylisoxazole, as represented by the formula:

wherein R represents a substituent member selected from the group consisting of amino, acylamino, nitro and carbo alkoxyarnino radicals, and treating said reaction product for the separation and recovery of the desired 3-sulfanilamido-S-methylisoxazole.

References Cited in the file of this patent UNITED STATES PATENTS Wuest Nov. 4, 1947 OTHER REFERENCES Backer et al.: Rec. Trav. Chin1., vol. 61, pp. 461-466 (1942).

Musante: Gazz. Chim. Ital., vol. 71, pp. 565-573 (1941).

Anderson: Iourn. of the American Chemical Society, vol. 64, pp. 2902-5 (1942).

Claims (1)

1. THE CHEMICAL COMPOUND 3-SULFANILAMIDO-5-METHYLISOXAZOLE, AS REPRESENTED BY THE FORMULA:
US2888455A 1956-09-04 1957-09-03 New sulfonamide and process for producing the same Expired - Lifetime US2888455A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2888455X 1956-09-04

Publications (1)

Publication Number Publication Date
US2888455A true US2888455A (en) 1959-05-26

Family

ID=17735487

Family Applications (1)

Application Number Title Priority Date Filing Date
US2888455A Expired - Lifetime US2888455A (en) 1956-09-04 1957-09-03 New sulfonamide and process for producing the same

Country Status (1)

Country Link
US (1) US2888455A (en)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3085937A (en) * 1960-11-21 1963-04-16 Shionogi & Co Method of combating coccidiosis with sulfonamide compositions
US3138524A (en) * 1962-06-06 1964-06-23 Hoffmann La Roche Pharmaceutical suspensions
US3144448A (en) * 1964-08-11 Isoxazole derivatives of sulfanilamide
US3157669A (en) * 1962-07-17 1964-11-17 Hoffmann La Roche Preparation of isoxazole compounds
US3227613A (en) * 1962-12-06 1966-01-04 Shionogi & Co Method of producing prolonged sulfonamide level in blood
US3251840A (en) * 1961-06-17 1966-05-17 Acraf 3-sulfamyl phenyl-5-aminoalkyl-1, 2, 4-oxadiazoles
DE1263771B (en) * 1962-08-21 1968-03-21 Shionogi & Co A process for the preparation of 3-sulfanilamido-4-iodo-5-methylisoxazole
US4062861A (en) * 1973-07-27 1977-12-13 Shionogi & Co., Ltd. 3-Isoxazolylurea derivatives
EP0558258A1 (en) * 1992-02-24 1993-09-01 E.R. SQUIBB & SONS, INC. N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5916907A (en) * 1997-01-30 1999-06-29 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5958905A (en) * 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6043265A (en) * 1997-01-30 2000-03-28 Bristol-Myers Squibb Co. Isoxazolyl endothelin antagonists
US6080774A (en) * 1995-10-11 2000-06-27 Bristol-Myers Squibb Company Substituted biphenylsulfonamide endothelin antagonists
US6248767B1 (en) 1997-04-28 2001-06-19 Texas Biotechnology Corp. Formulation of sulfonamides for treatment of endothelin-mediated disorders
US6313308B1 (en) 1999-03-19 2001-11-06 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US6432994B1 (en) 1997-04-28 2002-08-13 Texas Biotechnology Corporation Sulfonamides for treatment of endothelin-mediated disorders
US6515136B1 (en) 1996-02-20 2003-02-04 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US6573254B1 (en) 1998-02-03 2003-06-03 University Of Maryland Method for the stimulation of sperm production and gonadal development in animals
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2430094A (en) * 1947-11-04 Isoxazole derivatives of

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2430094A (en) * 1947-11-04 Isoxazole derivatives of

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3144448A (en) * 1964-08-11 Isoxazole derivatives of sulfanilamide
US3085937A (en) * 1960-11-21 1963-04-16 Shionogi & Co Method of combating coccidiosis with sulfonamide compositions
US3251840A (en) * 1961-06-17 1966-05-17 Acraf 3-sulfamyl phenyl-5-aminoalkyl-1, 2, 4-oxadiazoles
US3138524A (en) * 1962-06-06 1964-06-23 Hoffmann La Roche Pharmaceutical suspensions
US3157669A (en) * 1962-07-17 1964-11-17 Hoffmann La Roche Preparation of isoxazole compounds
DE1263771B (en) * 1962-08-21 1968-03-21 Shionogi & Co A process for the preparation of 3-sulfanilamido-4-iodo-5-methylisoxazole
US3227613A (en) * 1962-12-06 1966-01-04 Shionogi & Co Method of producing prolonged sulfonamide level in blood
US4062861A (en) * 1973-07-27 1977-12-13 Shionogi & Co., Ltd. 3-Isoxazolylurea derivatives
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
EP0558258A1 (en) * 1992-02-24 1993-09-01 E.R. SQUIBB & SONS, INC. N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US6107320A (en) * 1992-05-06 2000-08-22 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US6331637B1 (en) 1993-10-21 2001-12-18 Texas Biotechnology Corporation N-Alkyl, N-Alkenyl, N-Alkynyl, N-Aryl and N-fused bicyclo or tricyclo thienyl-, furyl-,and Pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5827869A (en) * 1994-08-26 1998-10-27 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US6080774A (en) * 1995-10-11 2000-06-27 Bristol-Myers Squibb Company Substituted biphenylsulfonamide endothelin antagonists
US6271248B1 (en) 1995-10-11 2001-08-07 Bristol-Myers Squibb Company Substituted biphenysulfonamide endothelin antagonists
US6265428B1 (en) 1996-01-05 2001-07-24 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US6515136B1 (en) 1996-02-20 2003-02-04 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US5958905A (en) * 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US6384261B1 (en) 1996-03-26 2002-05-07 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US6632829B2 (en) 1996-04-04 2003-10-14 Texas Biotechnology Corp. Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US6013655A (en) * 1996-04-15 2000-01-11 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
US6329387B2 (en) 1996-04-15 2001-12-11 Texas Biotechnology Corporation. Use of thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
US6545014B2 (en) 1996-04-15 2003-04-08 Texas Biotechnology Corporation Method of treating glaucoma
US6420567B1 (en) 1996-09-27 2002-07-16 Texas Biotechnology Corporation N-heteroaryl aryl-substituted thienyl-furyl-and pyrrolyl-sulfonamides and derviatives thereof that modulate the activity of endothelin
US20030208084A1 (en) * 1996-09-27 2003-11-06 Chengde Wu Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5916907A (en) * 1997-01-30 1999-06-29 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
US6043265A (en) * 1997-01-30 2000-03-28 Bristol-Myers Squibb Co. Isoxazolyl endothelin antagonists
US6683103B2 (en) 1997-04-28 2004-01-27 Texas Biotechnology Corporation Sulfonamides for treatment of endothelin-mediated disorders
US6458805B2 (en) 1997-04-28 2002-10-01 Texas Biotechnology Corporation Formulation of sulfonamides for treatment of endothelin-mediated disorders
US6432994B1 (en) 1997-04-28 2002-08-13 Texas Biotechnology Corporation Sulfonamides for treatment of endothelin-mediated disorders
US6248767B1 (en) 1997-04-28 2001-06-19 Texas Biotechnology Corp. Formulation of sulfonamides for treatment of endothelin-mediated disorders
US6573254B1 (en) 1998-02-03 2003-06-03 University Of Maryland Method for the stimulation of sperm production and gonadal development in animals
US6313308B1 (en) 1999-03-19 2001-11-06 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides

Similar Documents

Publication Publication Date Title
US3300488A (en) Nu, nu'-bis [4-halogenated-5-alkyl-3-isoxazolylsulfamoyl)-phenyl]-ureas
US3316266A (en) 3-aminopyrazinoic acid derivatives and process for their preparation
US2997471A (en) Tetracycline derivatives
Roblin Jr et al. Chemotherapy. II. Some Sulfanilamido Heterocycles1
US3178478A (en) 2-amino-5-halo-indanes
US2745875A (en) Preparation of nu-acylamino-phenylpropane diols
US2358031A (en) Substituted thiadiazoles
Ainsworth The condensation of carboxylic acid hydrazides with carbon disulfide
US2913454A (en) Certain cycloalkanotriazoles, process and intermediates
US20080096874A1 (en) Oxadiazole Derivative as Dgat Inhibitors
US3072653A (en) 5-amino derivatives of 4-thiazolidinones and process therefor
US3873579A (en) Organic azides and method of preparation thereof
EP0339854B1 (en) Synthesis of n-t-alkyl-1,2-diacylhydrazines
US3491091A (en) 5-nitrofuran derivatives
US2742500A (en) Resolution of phenylaminopropanediols and intermediates
US2435002A (en) Process for the manufacture of para-aminobenzene-sulphonamidopyrimidines
US2744908A (en) Process for preparing substitutedmercapto-1, 3, 4-thiadiazoles
US2027031A (en) Oxazoline compound
US2675409A (en) Preparation of 2, 4, 6-trichloroaniline
US2541717A (en) Pterine imines
US2460803A (en) Disubstituted desoxyalditols and process for their preparation
US2969364A (en) Derivatives of 5-amino uracil
US2868803A (en) New pyrazoles and method of preparing same
US2324013A (en) Amino-substituents of sulphanil-amide derivatives
US2376424A (en) Biological product and process of obtaining same